News

  RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic companion radiopharmaceuticals to address unmet needs in oncology. Michael Lee-Chin appointed to the board of the company.     Houston, Texas and Burlington, Ontario, October 6th, 2022 – RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage biotechnology company announced the arrangement with Portland Investment Counsel Inc. (“Portland”) to complete an equity round of $40 million of a Series A funding round. Radiomedix is committed to the advancement of a targeted alpha therapy (TAT) pipeline and diagnostic companion radiopharmaceuticals for rare and...

Houston, TX and Plano, TX, Jan. 03, 2022 RadioMedix and Orano Med are pleased to announce the initiation of the Phase II clinical trial of AlphaMedix™ with the treatment of the first patient on December 21st, 2021.  This trial will evaluate the safety and effectiveness of 212Pb-DOTAMTATE (AlphaMedix™) in Peptide Receptor Radionuclide Therapy (PRRT) of naive patients with somatostatin receptor-expressing neuroendocrine tumors (NET).  “The initiation of the Phase II trial is a significant milestone in the clinical development of our innovative targeted alpha-emitter radiotherapy and brings us one step closer to having this drug available for our patients”, said Ebrahim Delpassand,...

RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Phase Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute at the US National Institutes of Health . The grant supports Phase I/II clinical development of innovative alpha-emitter labeled peptide, AlphaMedixTM,  for therapy of somatostatin receptor positive neuroendocrine tumors. RadioMedix successfully completed Phase I and Phase II NCI SBIR Contracts  focused on the dose escalation and safety studies of AlphaMedix in PRRT-naïve neuroendocrine patients. The Phase II SBIR funding will be used to evaluate additional safety and efficacy...

The AIM-HI Accelerator Fund just announced 10 semi-finalists for the 2021 Women’s Venture Competition! These oncology companies have been selected from among an exceptional pool of applications submitted globally by women scientist-entrepreneurs. Decision making was led by a selection committee comprised of world-class key opinion leaders, life sciences industry experts, investors, and entrepreneurs. The Women’s Venture Competition is a first-of-its-kind program that provides funding, coaching, and networking opportunities to women-led oncology start-ups. The chosen semi-finalists are advancing to a virtual competition being conducted on August 2, 2021. The winning company, to be determined by a word-class judging committee, will receive a total...

Houston-Texas August 2nd, 2021 Excel Diagnostics and Nuclear Oncology Center (EDNOC), a premier Diagnostic Imaging and Radioligand Therapy   center in Houston, Texas announces approval of its physicians sponsored Investigational New Drug (IND) application for providing Targeted Alpha Therapy (TAT) with 225Ac-PSMA I&T for metastatic Castration Resistant Prostate Cancer (mCRPC).  “We are glad to be able to make this game changing drug available to our patients suffering from mCRPC.  Excel Diagnostics and Nuclear Oncology Center has been a pioneer in bringing new targeted Radioligand Therapies such as Lu-177 DOTATATE, and Lu-177 PSMA to serve our patients in the United States. The...